Simvastatin reverses the hypertension of heterozygous mice lacking cystathionine β-synthase and apolipoprotein A-I

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 377, Issue 1, 2008, Pages 35-43

  Carnicer, Ricardo ^a   Navarro, María A ^a   Guillén, Natalia ^a,b   Arbonés Mainar, José M ^a   Surra, Joaquín C ^a,b   Acín, Sergio ^a   Osada, Jesús ^a,b,c  

^a CENTRO DE INVESTIGACIÓN Y TECNOLOGÍA AGROALIMENTARIA DE ARAGÓN CITA   (Spain)

^b Instituto de Salud Carlos III   (Spain)

^c UNIVERSIDAD DE ZARAGOZA   (Spain)

Author keywords

High density lipoproteins; Homocysteine; Hypertension; Nitric oxide; Simvastatin

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN A4; ARYLDIALKYLPHOSPHATASE; ARYLESTERASE; CAVEOLIN 1; CHOLESTEROL; CYSTATHIONINE BETA SYNTHASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; NITRIC OXIDE; SIMVASTATIN; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE VARIABILITY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; HYPERTENSION; MALE; MOUSE; NONHUMAN; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; VASCULAR ENDOTHELIUM; WESTERN BLOTTING; WILD TYPE;

ANIMALS; ANTIHYPERTENSIVE AGENTS; AORTA; APOLIPOPROTEIN A-I; BLOOD PRESSURE; BLOTTING, WESTERN; CHROMATOGRAPHY, LIQUID; CYSTATHIONINE BETA-SYNTHASE; ENDOTHELIUM, VASCULAR; HETEROZYGOTE; HYPERTENSION; LIPOPROTEINS; MALE; MICE; NITRATES; NITRIC OXIDE; NITRITES; SIMVASTATIN;

EID: 39149136867     PISSN: 00281298     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00210-007-0247-6     Document Type: Article

References (46)

1. Acin S, Navarro MA, Carnicer R, Arbones-Mainar JM, Guzman MA, Arnal C, Beltran G, Uceda M, Maeda N, Osada J (2005) Dietary cholesterol suppresses the ability of olive oil to delay the development of atherosclerotic lesions in apolipoprotein E knockout mice. Atherosclerosis 182:17-28
2. Alberts AW (1988) Discovery, biochemistry and biology of lovastatin. Am J Cardiol 62:10J-15J
3. Alonso-Orgaz S, Moreno L, Macaya C, Rico L, Mateos-Caceres PJ, Sacristan D, Perez-Vizcaino F, Segura A, Tamargo J, Lopez-Farre A (2006) Proteomic study of plasma from moderate hypercholesterolemic patients. J Proteome Res 5:2301-2308
4. Arbones-Mainar JM, Navarro MA, Carnicer R, Guillen N, Surra JC, Acin S, Guzman MA, Sarria AJ, Arnal C, Aguilera MP, Jimenez A, Beltran G, Uceda M, Osada J (2007) Accelerated atherosclerosis in apolipoprotein E-deficient mice fed Western diets containing palm oil compared with extra virgin olive oils: a role for small, dense high-density lipoproteins. Atherosclerosis 194:372-382
5. Asztalos BF, Horvath KV, McNamara JR, Roheim PS, Rubinstein JJ, Schaefer EJ (2002) Effects of atorvastatin on the HDL subpopulation profile of coronary heart disease patients. J Lipid Res 43:1701-1707
6. Augustyniak RA, Thomas GD, Victor RG, Zhang W (2005) Nitric oxide pathway as new drug targets for refractory hypertension. Curr Pharm Des 11:3307-3315
7. Bayorh MA, Ganafa AA, Eatman D, Walton M, Feuerstein GZ (2005) Simvastatin and losartan enhance nitric oxide and reduce oxidative stress in salt-induced hypertension. Am J Hypertens 18:1496-1502
8. Borghi C, Prandin MG, Costa FV, Bacchelli S, Degli Esposti D, Ambrosioni E (2000) Use of statins and blood pressure control in treated hypertensive patients with hypercholesterolemia. J Cardiovasc Pharmacol 35:549-555
9. Calleja L, Paris MA, Paul A, Vilella E, Joven J, Jimenez A, Beltran G, Uceda M, Maeda N, Osada J (1999) Low-cholesterol and high-fat diets reduce atherosclerotic lesion development in ApoE-knockout mice. Arterioscler Thromb Vasc Biol 19:2368-2375
10. Carnicer R, Navarro MA, Arbones-Mainar JM, Arnal C, Surra JC, Acin S, Sarria A, Blanco-Vaca F, Maeda N, Osada J (2007) Genetically based hypertension generated through interaction of mild hypoalphalipoproteinemia and mild hyperhomocysteinemia. J Hypertens 25:1597-1607
11. Deakin S, Leviev I, Guernier S, James RW (2003) Simvastatin modulates expression of the PON1 gene and increases serum paraoxonase: a role for sterol regulatory element-binding protein-2. Arterioscler Thromb Vasc Biol 23:2083-2089
12. Delbosc S, Cristol JP, Descomps B, Mimran A, Jover B (2002) Simvastatin prevents angiotensin II-induced cardiac alteration and oxidative stress. Hypertension 40:142-147
13. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM, Jr. (1998) Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279:1615-1622
14. Escola-Gil JC, Jorba O, Julve-Gil J, Gonzalez-Sastre F, Ordonez-Llanos J, Blanco-Vaca F (1999) Pitfalls of direct HDL-cholesterol measurements in mouse models of hyperlipidemia and atherosclerosis. Clin Chem 45:1567-1569
15. Feron O, Dessy C, Desager JP, Balligand JL (2001) Hydroxy-methylglutaryl- coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance. Circulation 103:113-118
16. Forte P, Copland M, Smith LM, Milne E, Sutherland J, Benjamin N (1997) Basal nitric oxide synthesis in essential hypertension. Lancet 349:837-842
17. Forte TM, Oda MN, Knoff L, Frei B, Suh J, Harmony JA, Stuart WD, Rubin EM, Ng DS (1999) Targeted disruption of the murine lecithin:cholesterol acyltransferase gene is associated with reductions in plasma paraoxonase and platelet-activating factor acetylhydrolase activities but not in apolipoprotein J concentration. J Lipid Res 40:1276-1283
18. Gewaltig MT, Kojda G (2002) Vasoprotection by nitric oxide: mechanisms and therapeutic potential. Cardiovasc Res 55:250-260
19. Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, Sanchez-Pascuala R, Hernandez G, Diaz C, Lamas S (1998) Effects of the 3-hydroxy-3-methylglutaryl- CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 101:2711-2719
20. Jimenez AM, Millas I, Farre J, Garcia-Mendez A, Jimenez P, Arriero MM, Garcia-Colis E, de Andres R, Gomez J, Casado S, Lopez-Farre A (2002) Effect of HMG-CoA reductase inhibition on endothelial dysfunction-inducing protein in hypercholesterolemic rabbits. Rev Esp Cardiol 55:1151-1158
21. Koh KK, Son JW, Ahn JY, Kim DS, Jin DK, Kim HS, Han SH, Seo YH, Chung WJ, Kang WC, Shin EK (2004) Simvastatin combined with ramipril treatment in hypercholesterolemic patients. Hypertension 44:180-185
22. Laufs U, La Fata V, Plutzky J, Liao JK (1998) Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 97:1129-1135
23. Laufs U, Gertz K, Dirnagl U, Bohm M, Nickenig G, Endres M (2002) Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice. Brain Res 942:23-30
24. Liao JK (2005) Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol. Am J Cardiol 96:24F-33F
25. Martin G, Duez H, Blanquart C, Berezowski V, Poulain P, Fruchart JC, Najib-Fruchart J, Glineur C, Staels B (2001) Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I. J Clin Invest 107:1423-1432
26. Martinez-Gonzalez J, Raposo B, Rodriguez C, Badimon L (2001) 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition prevents endothelial NO synthase downregulation by atherogenic levels of native LDLs: balance between transcriptional and posttranscriptional regulation. Arterioscler Thromb Vasc Biol 21:804-809
27. Martinez-Gonzalez J, Escudero I, Badimon L (2004) Simvastatin potentiates PGI(2) release induced by HDL in human VSMC: effect on Cox-2 up-regulation and MAPK signalling pathways activated by HDL. Atherosclerosis 174:305-313
28. Mason RP, Walter MF, Jacob RF (2004) Effects of HMG-CoA reductase inhibitors on endothelial function: role of microdomains and oxidative stress. Circulation 109:II34-II41
29. Misko TP, Schilling RJ, Salvemini D, Moore WM, Currie MG (1993) A fluorometric assay for the measurement of nitrite in biological samples. Anal Biochem 214:11-16
30. Murata T, Kinoshita K, Hori M, Kuwahara M, Tsubone H, Karaki H, Ozaki H (2005) Statin protects endothelial nitric oxide synthase activity in hypoxia-induced pulmonary hypertension. Arterioscler Thromb Vasc Biol 25:2335-2342
31. Nakata S, Tsutsui M, Shimokawa H, Yamashita T, Tanimoto A, Tasaki H, Ozumi K, Sabanai K, Morishita T, Suda O, Hirano H, Sasaguri Y, Nakashima Y, Yanagihara N (2007) Statin treatment upregulates vascular neuronal nitric oxide synthase through Akt/NF-kappa B pathway. Arterioscler Thromb Vasc Biol 27:92-98
32. Navarro MA, Carpintero R, Acin S, Arbones-Mainar JM, Calleja L, Carnicer R, Surra JC, Guzman-Garcia MA, Gonzalez-Ramon N, Iturralde M, Lampreave F, Pineiro A, Osada J (2005) Immune-regulation of the apolipoprotein A-I/C-III/A-IV gene cluster in experimental inflammation. Cytokine 31:52-63
33. Ostos MA, Conconi M, Vergnes L, Baroukh N, Ribalta J, Girona J, Caillaud JM, Ochoa A, Zakin MM (2001) Antioxidative and antiatherosclerotic effects of human apolipoprotein A-IV in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 21:1023-1028
34. Rashid S, Uffelman KD, Barrett PH, Lewis GF (2002) Effect of atorvastatin on high-density lipoprotein apolipoprotein A-I production and clearance in the New Zealand white rabbit. Circulation 106:2955-2960
35. Rezaie-Majd A, Prager GW, Bucek RA, Schernthaner GH, Maca T, Kress HG, Valent P, Binder BR, Minar E, Baghestanian M (2003) Simvastatin reduces the expression of adhesion molecules in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol 23:397-403
36. Rosenson RS (2004) Statins in atherosclerosis: lipid-lowering agents with antioxidant capabilities. Atherosclerosis 173:1-12
37. Sbaa E, Frerart F, Feron O (2005) The double regulation of endothelial nitric oxide synthase by caveolae and caveolin: a paradox solved through the study of angiogenesis. Trends Cardiovasc Med 15:157-162
38. Scalia R, Gooszen ME, Jones SP, Hoffmeyer M, Rimmer DM, 3rd, Trocha SD, Huang PL, Smith MB, Lefer AM, Lefer DJ (2001) Simvastatin exerts both anti-inflammatory and cardioprotective effects in apolipoprotein E-deficient mice. Circulation 103:2598-2603
39. Schaefer JR, Schweer H, Ikewaki K, Stracke H, Seyberth HJ, Kaffarnik H, Maisch B, Steinmetz A (1999) Metabolic basis of high density lipoproteins and apolipoprotein A-I increase by HMG-CoA reductase inhibition in healthy subjects and a patient with coronary artery disease. Atherosclerosis 144:177-184
40. Tailleux A, Torpier G, Mezdour H, Fruchart JC, Staels B, Fievet C (2003) Murine models to investigate pharmacological compounds acting as ligands of PPARs in dyslipidemia and atherosclerosis. Trends Pharmacol Sci 24:530-534
41. Timmins JM, Lee JY, Boudyguina E, Kluckman KD, Brunham LR, Mulya A, Gebre AK, Coutinho JM, Colvin PL, Smith TL, Hayden MR, Maeda N, Parks JS (2005) Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I. J Clin Invest 115:1333-1342
42. Todd PA, Goa KL (1990) Simvastatin. A review of its pharmacological properties and therapeutic potential in hypercholesterolaemia. Drugs 40:583-607
43. Vowinkel T, Mori M, Krieglstein CF, Russell J, Saijo F, Bharwani S, Turnage RH, Davidson WS, Tso P, Granger DN, Kalogeris TJ (2004) Apolipoprotein A-IV inhibits experimental colitis. J Clin Invest 114:260-269
44. Watanabe M, Osada J, Aratani Y, Kluckman K, Reddick R, Malinow MR, Maeda N (1995) Mice deficient in cystathionine beta-synthase: animal models for mild and severe homocyst(e)inemia. Proc Natl Acad Sci USA 92:1585-1589
45. Williamson R, Lee D, Hagaman J, Maeda N (1992) Marked reduction of high density lipoprotein cholesterol in mice genetically modified to lack apolipoprotein A-I. Proc Natl Acad Sci USA 89:7134-7138
46. Yamamoto E, Yamashita T, Tanaka T, Kataoka K, Tokutomi Y, Lai ZF, Dong YF, Matsuba S, Ogawa H, Kim-Mitsuyama S (2007) Pravastatin enhances beneficial effects of olmesartan on vascular injury of salt-sensitive hypertensive rats, via pleiotropic effects. Arterioscler Thromb Vasc Biol 27:556-563